Tuesday, September 26, 2023


Biotechnology News Magazine

Active Motif Incorporated Announces the Acquisition of Amaryllis Nucleics

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Active Motif Incorporated, a company with the vision of bringing epigenetics more deeply into precision medicine, announced that it has purchased Amaryllis Nucleics, a Bay Area-based start-up company focused on proprietary RNA Sequencing methods.

Amaryllis Nucleics provides Active Motif with a streamlined, low-cost library preparation method to perform high-efficiency RNA sequencing using their intellectual property associated with 3′ Digital Gene Expression. The technology utilizes a novel synthesis chemistry that is twice as fast from RNA to library prep compared to other methods, is less expensive, and shows greater than 99% strand-specificity. Amaryllis’ service business as well as their 3′ DGE RNA Library Prep Kit will be integrated into the Active Motif portfolio.

Dr. Brad Townsley, co-inventor and co-owner of Amaryllis Nucleics stated, “We are excited to join forces with Active Motif to demonstrate and promote the full value of our RNA sequencing technology that leverages our 3 prime tagging strategy. Our technology is well suited for Differential Gene Expression (DGE) as well as for discovery projects and high throughput screening projects where RNA is being assessed for SNP genotyping and other relevant variants. Amaryllis Nucleics has been providing customers an end-to-end solution with shorter turn-around times from RNA to library prep with complete data analysis at a lower cost per sample compared to whole transcriptome sequencing approaches for RNASeq.”

Active Motif has begun the transition of both the kit manufacturing as well as the custom service business of Amaryllis Nucleics while keeping business continuity with the existing Amaryllis customer base. “We feel as if we have identified a novel, highly differentiated method for interrogating RNA that will fit nicely into our portfolio and aid us in the enablement and advancement of precision medicine” noted Ted DeFrank, President and CEO of Active Motif.

Details about Amaryllis Nucleics 3’DGE RNA sequencing products and services can be found at https://amaryllisnucleics.com

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine